Introduction {#s1}
============

Liver cancer is the sixth most common cancer and the fourth leading cause of cancer-related deaths ([@B1]). Specifically, hepatocellular carcinoma (HCC) accounts for more than 90% of liver cancer cases from a histopathological perspective. According to the GLOBOCAN 2018 database, there are about 841,000 new HCC cases and 782,000 related deaths worldwide each year, with China accounting for nearly half of the total number of global HCC cases and deaths ([@B2], [@B3]). In China, the Guangxi province has higher morbidity and mortality rates than the national average ([@B4]). The high mortality and poor prognosis of HCC poses a global challenge. Despite the slight increase in the 5-year survival rate of liver cancer in China from 10.1 to 12.1% over the periods of 2003--2015, it still remains at a low level ([@B5]). A survival analysis of 2, 887 liver cancer patients in 14 years showed that the 1-year, 3-year, and 5-year survival rates were 49.3, 26.6, and 19.5%, respectively ([@B6]).

Although there are many existing therapies for HCC including surgical resection, transplantation, ablation, and transcatheter chemoembolization, etc., the long-term survival of HCC patients remains poor due to their limited indications and different effects on prognosis ([@B7]--[@B10]). A 20-year prospective cohort analysis reported that the 5-year survival rates of TNM stage I, II, IIIA, and IVA patients after hepatectomy were 81.7, 77.2, 44, and 28.2%, respectively ([@B11]). Therefore, it is of crucial importance to explore new prognostic biomarkers and investigate treatment strategies to improve the overall prognosis of HCC patients.

Currently, the research on prognostic molecular markers of HCC is still ongoing, and many single-gene or multi-gene combination molecular markers related to HCC invasion, metastasis and prognosis are being gradually discovered. For example, the expression of *HMGA1* in HCC is associated with poor prognosis and is found to promote tumor growth and migration *in vitro* ([@B12]). The overexpression of *SYPL1* is associated with epithelial-mesenchymal transition (EMT) of HCC cells and can predict the prognosis of HCC ([@B13]). *RBM8A* and *SIRT5* promote the migration and invasion of HCC cells by activating the EMT signaling pathway and targeting *E2F1* ([@B14], [@B15]), respectively ([@B16], [@B17]). The *EpCAM* ([@B18]), a liver X receptor (*LXR*) ([@B19]), *SPAG5* ([@B20]), and *KOR* ([@B21]) have been shown to be strongly correlated with HCC metastasis, invasion, or prognosis. Arginase-1, *FTCD*, and *MOC-31* have a good performance in the diagnosis of HCC ([@B22]). *TMEM88, CCL14*, and *CLEC3B* can serve as potential prognostic markers of HCC ([@B23]). At the same time, some multi-gene combined prognostic studies on HCC have also been reported. For example, three genes (*UPB1, SOCS2, RTN3*) combination markers ([@B24]) and four genes (*CENPA, SPP1, MAGEB6, HOXD9*) combination models can predict the overall survival in patients with HCC prognosis ([@B25]).

However, due to the sample size limitation and the heterogeneity of the samples in different studies, the efficiency of the identified prognostic markers for liver cancer still has ample space to improve. In addition, because of the myriad of gene interaction capabilities and the possibility of synergistic promotion of disease progression, it is of great significance to find some multi-gene combinations that may have better prognostic efficacy than single genes for prognostic targets of liver cancer. Therefore, the leverage of the large sample sizes of the public data platforms, integrating new and effective mining and screening methods, as well as reliable experimental verification is a very promising direction for the discovery of multiple effective single genes and multi-gene combination prognostic markers of liver cancer.

High-throughput profiling technologies and bioinformatics methods are now being applied to all fields of biomedical research. A mass of cancer data, such as the mRNA expression, copy number variation, single nucleotide polymorphism (SNP), and microRNA expression generated by those tools are collected in public archives such as The Cancer Genome Atlas (TCGA) (<http://cancergenome.nih.gov/>), Coremine (<http://www.coremine.com/medical/>), Oncomine (<https://www.oncomine.org/resource/login.html>), Gene Expression Omnibus database (GEO, <https://www.ncbi.nlm.nih.gov/geo/>), etc. Making full use of the public data from these databases is meaningful for exploring and discovering effective HCC prognostic biomarkers. For instance, Li et al. ([@B24]) developed a three-gene prognostic signature composing of three genes *UPB1, SOCS2*, and *RTN3*, which was revealed to have prognostic value for HCC patients based on TCGA data. Our previous study used data retrieved from the Coremine, TCGA, and GEO database and discovered that high-expressed E2F transcription factor 3 is associated with poor prognosis of HCC ([@B26]).

In this study, we used text mining approach to find the medial related candidate gene list for liver cancer prognosis, and a total of 1,173 genes that might be related to the prognosis of liver cancer were finally obtained. The association of the 1,173 genes with overall survival (OS) and disease-free survival (DFS) was accessed in a large sample of TCGA cohort, in which the subgroups of 319 patients with DFS and 370 with OS were available. The survival analyses are carried out for each of these genes to identify single prognostic markers. Moreover, we performed survival analyses of the gene combinations and performed multiple screening for these HCC prognostic molecular markers, revealing the association between the expression of numerous genes or gene combinations and the survival in HCC patients. We then compared the ability of single genes and multiple gene combinations to predict the prognosis of HCC. Moreover, a huge difference between high and low expression group of these three-gene combinations was detected, with median survival difference of DFS up to 65.01 months, and of OS up to 83.57 months. The high or low expression group of these three-gene combinations can predict the longest prognosis of DFS and OS is 71.91 months and 102.66 months, and the shortest is 6.24 months and 13.96 months. Among the above genes that may be strongly correlated with the prognosis of HCC identified in large sample data, it was found that the combination of the three genes *F2, GOT2*, and *TRPV1* that have not been systematically reported has a strong ability to predict the prognosis of HCC. We further verified *F2, GOT2*, and *TRPV1* by three independent expression profile microarray data for liver cancer acquired from the Oncomine database, and conducted the quantitative real-time polymerase chain reaction (qRT-PCR) in 20 pairs of HCC and adjacent tissues, and immunohistochemistry (IHC) staining in 90 pairs of HCC and its precancerous tissues. These results validated that the low expression of *F2, GOT2*, and *TRPV1* in liver cancer was associated with the poor prognosis of liver cancer.

Materials and Methods {#s2}
=====================

Data Sources
------------

We combined 3 corresponding concepts of the key word "liver cancer" with 2 concepts of the key word "prognosis" and 10 concepts of the key word "outcome," respectively, ([Supplementary Table S1](#SM1){ref-type="supplementary-material"}), and searched for their corresponding genes or proteins in the Coremine database (<http://www.coremine.com/medical/>). After deleting duplicates, we selected 1,173 gene entries with *p*-values \< 0.05 that might be associated with the prognosis of liver cancer for further analyses ([Supplementary Table S2](#SM1){ref-type="supplementary-material"}).

The above genes mined in the Coremine database include some genes obtained from other gene-mining reports; however, the number of samples and data standards in each report is different. Therefore, we selected the cohort of The Cancer Genome Atlas (TCGA) (<http://cancergenome.nih.gov/>), a database with consistent sample size and data standards, to conduct unified batch verification of these genes and conduct three-gene combinations survival analyses.

We studied the relationship between each of the selected 1,173 genes and the prognosis of liver cancer patients in TCGA cohort which downloaded from cBioPortal for Cancer Genomics (<https://www.cbioportal.org/>) in September 2018 ([@B27], [@B28]), and a subgroup of 319 liver cancer samples with HCC DFS corresponding follow-up data and a subgroup of 370 liver cancer samples with HCC OS corresponding follow-up data were chosen.

Survival Analysis and Gene Selection
------------------------------------

Kaplan-Meier estimation of survival functions and Log-rank tests were used to evaluate effect of genes on DFS and OS. The Cox proportional hazard model was performed for multivariate analyses of HCC prognosis. Survival analyses were performed using the R survival package in R (version 3.3.1). The Kaplan-Meier survival curves and Cox proportional hazards regression model for DFS and OS were generated by IBM SPSS (version 23.0). The median expression level of a gene was used as a cutoff value for the classification of patients into high and low expression groups ([@B29]).

Human Tissue Samples
--------------------

For the validation studies, we used 20 patients who underwent primary and curative hepatectomy from Apr 2016 to Apr 2018 at the First Affiliated Hospital of Guangxi Medical University. Those patients who have distinctive pathologic diagnosis of HCC without preoperative anticancer treatment were eligible for inclusion in this study. The paraffin-embedded pathologic specimens were collected during surgery and stored in a liquid nitrogen tank until the step of mRNA isolation. All patients received an explanation for the purpose of the study and signed informed consent. The Ethics Committee of Guangxi Medical University granted approval for this study. For IHC, a commercial biological tissue microarray containing 90 pairs of HCC and adjacent normal liver tissues was constructed by the Biological sample library of Shanghai Outdo Biotech Company, and the survival information of each case was usable. (Microarray: HLivH180Su14).

Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
----------------------------------------------------------

QRT-PCR was performed to evaluate the mRNA expression of selected genes in 20 HCC and their matched precancerous tissues. Total RNA was isolated using Trizol reagent (Life Technologies, Inc., NY, USA) according to the manufacturer\'s instructions. The concentration and purity of the total RNA were detected using Microplate reader (Bioteck Instruments, Inc., VT, USA). RNA reverse transcription was then performed with the PrimeScript™ RT reagent Kit (Takara Biomedical Technology (Beijing) Co., Ltd.) with gDNA Eraser (Perfect Real Time), and qRT-PCR was performed using the TB GreenTM Premix Ex TaqTM II (Tli RNaseH Plus) kit (Takara Biomedical Technology (Beijing) Co., Ltd.) protocol in a StepOnePlus system (Applied Biosystems. Life Technologies Holdings Pte Ltd, Singapore).

The sequences of the primers are as follows: *F2*: forward primer, 5′-CTGAGGGTCTGGGTACGAACT-3′, reverse primer, 5′-TGGGTAGCGACTCCTCCATAG-3′; *GOT2*: forward primer, 5′-AAGAGTGGCCGGTTTGTCAC-3′, reverse primer, 5′-AGAAAGACATCTCGGCTGAACT-3′; *TRPV1*: forward primer, 5′-TGCACGACGGACAGAACAC-3′, reverse primer, 5′-GCGTTGACAAGCTCCTTCAG-3′. The cycle conditions are as follows: after an initial incubation at 95°C for 30 s, the samples were cycled 40 times at 95°C for 5 s and 60°C for 30 s. The relative expression level of each gene in the individual samples was calculated using the 2^−^ΔΔ*Ct* method and normalized using GAPDH as an endogenous control.

Immunohistochemistry (IHC)
--------------------------

EnVision™ FLEX+, Mouse, High pH, (Link) (K8002, Dako) was used for the immunohistochemistry. After the tissue chips were baked and placed in LEICAST5010 (LEICA), PT Link (Dako North America, Inc.) was used for antigen retrieval. Primary antibodies were diluted (*F2*, 1:3000; *GOT2*, 1:80000; *TRPV1*, 1:1500) and incubated overnight at 4°C. The secondary antibody reactions were carried out using the Autostainer Link 48 (Dako North America, Inc.), the sections were subjected to color development with the DAB chromogenic kit, and finally counterstained with Hematoxylin (SLBT4555, Sigma Aldrich). The following antibodies were used: *F2*, 1: Anti-Thrombin (ab83981; Abcam), *GOT2*, 1: Anti-FABP-1 (ab171739; Abcam), *TRPV1*, 1: Anti-VR1 (ab3487; Abcam). All slides were evaluated by two independent pathologists who were blind about the clinicopathologic data.

The expression levels were scored as the staining intensity (0, negative; 1+, weak; 2+, moderate; 3+, strong) multiplied by the proportion of immunopositive staining area (0, \< 25%; 1+, 25--50%; 2+, 50--75%; 3+, \>75%) intensity of staining. Expression scores \<5 were considered as "low expression," and scores ≥5 were considered as "high expression."

Statistics
----------

Statistical analyses were conducted using R 3.3.1 (Auckland, NZ) and IBM SPSS 23.0 (Chicago, USA). McNemar test was used to test the paired 4-fold table experimental data of IHC. The paired *t*-test was used to analyze the qRT-PCR experimental data. Except for single-gene survival analyses and three-gene prognosis survival analyses with *p*-value \< 0.01 as statistically significant, other statistical analyses were considered statistically significant with two-sided *p*-value \< 0.05.

Results {#s3}
=======

Selection of Genes Related to Liver Cancer Prognosis and Liver Cancer Samples
-----------------------------------------------------------------------------

We combined 3 corresponding concepts of the key word "liver cancer" \[Liver neoplasms (alias Liver Cancer) (disease) (60,666 connections); Liver carcinoma (alias liver cell cancer) (disease) (55,739 connections); Carcinoma, Hepatocellular (alias Adult Liver Cancer) (mesh) (57,034 connections)\] with 2 corresponding concepts of the key word "prognosis" \[Prognosis (mesh) (77,312 connections); Prognostic Marker (alias Prognosis Marker) (chemical) (22,056 connections)\] and 10 corresponding concepts of the key word "outcome" \[Fatal Outcome (mesh) (34,016 connections); Outcome Assessment (Health Care) (alias Outcome Study) (mesh) (48,296 connections); Outcome studies (procedure) (9,545 connections); Treatment Outcome (mesh) (77,246 connections); Outcomes research (procedure) (5,540 connections); Outcome monitoring (procedure) (2,030 connections); Patient-focused outcomes (procedure) (3,830 connections); Treatment outcome in HSR (procedure) (998 connections); Patient Reported Outcome Measures (alias Patient Reported Outcome) (mesh) (2,301 connections); Patient Outcome Assessment (mesh) (9,066 connections)\], respectively, ([Supplementary Table S1](#SM1){ref-type="supplementary-material"}), and searched for their corresponding genes or proteins in the Coremine database (<http://www.coremine.com/medical/>). With *p*-values \< 0.05 as the criteria, a total of 1,173 genes that might be related to the prognosis of liver cancer were finally obtained after screening and elimination of duplicates. As the samples of liver cancer in the Coremine database were not uniform enough, we selected 319 samples for DFS and 370 samples for OS of liver cancer from the TCGA database and obtained the corresponding survival data as well as the expression information of the above 1,173 genes in these samples. This was necessary to carry out the subsequent survival analyses of these genes for liver cancer.

The Single Genes Prognostic Analyses
------------------------------------

To clearly describe our process of screening genes, a flowchart of the analysis procedure was developed ([Figure 1](#F1){ref-type="fig"}). First, we performed the Kaplan-Meier analysis of each of the 1,173 genes. It was found that the mRNA expression of 276 genes and 283 genes was significantly associated with DFS in 319 patients (*p* \< 0.05) and OS in 370 patients (*p* \< 0.05), respectively. Additionally, the mRNA expression of 166 of these genes was significantly associated with both DFS and OS (*p* \< 0.05).

![Flow Chart. ^\#^The associations of the genes with liver cancer prognosis that were not previously reported. \*By text mining of searching for key words related to the markers of liver cancer prognosis and screening, a total of 1,173 genes containing both previously reported and unreported associations with liver cancer prognosis were obtained. \*\*In each sample, the simultaneous high expression of all three genes was considered as high expression group in new combination. Similarly, the simultaneous low expression of all three genes was considered as low expression group in new combination. \*\*\*By comparing the prognostic value of individual genes and their combinations, we selected genes of combination *F2- GOT2-TRPV1* for subsequent verification.](fonc-10-00847-g0001){#F1}

To further investigate the value of the genes in the prognosis of liver cancer, we chose 135 genes and 149 genes with *p*-values \< 0.01 for DFS and OS, respectively. Next, we used the Cox proportional hazards regression model to employ multivariate analyses on the above genes, respectively to determine the DFS and OS prediction potential of these genes.

The DFS-related multivariate analysis results showed that the expression of 39 genes (*ALDOB, APOB, AURKB, C5, CCNF, CD4, CENPJ, CETP, COL18A1, CPT2, DAND5, DNASE1, EBPL, F7, FLT3, G6PD, GNMT, ITGB2, KLRK1, KNG1, LMOD1, NEK2, PCLAF, PER1, PKM, POU2F1, PPAT, PPIA, PRF1, PTPN6, RUNX3, SELP, SLCO1B1, SPPL2A, STAT5A, TCF21, TRPV1, TUSC1*, and *TYMS*) was significantly associated with DFS in HCC patients (*p* \< 0.05, [Table 1](#T1){ref-type="table"}). The highly significant results of both the DFS-related single-gene survival analyses for each of these 39 genes and multivariate analysis confirmed that the above 39 genes have a strong association with the DFS of liver cancer, especially the 5-year disease free survival rate of liver cancer.

###### 

Multivariate analyses of prognosis of DFS of 319 HCC patients and OS of 370 HCC patients in a TCGA cohort.

  **Items**        **Genes**                                    **B**    **SE**   **Wald**   **Sig**.   **Exp (B)**   **95.0% CI**   
  ---------------- -------------------------------------------- -------- -------- ---------- ---------- ------------- -------------- -------
  DFS associated   *ALDOB*                                      −0.580   0.186    9.750      0.002      0.560         0.389          0.806
                   *APOB*                                       −0.436   0.217    4.023      0.045      0.647         0.423          0.990
                   *AURKB*                                      0.527    0.211    6.208      0.013      1.694         1.119          2.564
                   *C5[^\*^](#TN1){ref-type="table-fn"}*        −0.420   0.170    6.093      0.014      0.657         0.471          0.917
                   *CCNF*                                       0.694    0.334    4.310      0.038      2.002         1.040          3.857
                   *CD4[^\*^](#TN1){ref-type="table-fn"}*       −0.774   0.316    6.007      0.014      0.461         0.248          0.856
                   *CENPJ*                                      1.053    0.243    18.794     0.000      2.867         1.781          4.615
                   *CETP[^\*^](#TN1){ref-type="table-fn"}*      0.829    0.423    3.851      0.050      2.291         1.001          5.245
                   *COL18A1[^\*^](#TN1){ref-type="table-fn"}*   0.417    0.207    4.064      0.044      1.518         1.012          2.278
                   *CPT2*                                       0.558    0.247    5.114      0.024      1.747         1.077          2.834
                   *DAND5[^\*^](#TN1){ref-type="table-fn"}*     −0.427   0.183    5.466      0.019      0.652         0.456          0.933
                   *DNASE1[^\*^](#TN1){ref-type="table-fn"}*    0.382    0.136    7.927      0.005      1.465         1.123          1.910
                   *EBPL[^\*^](#TN1){ref-type="table-fn"}*      −0.766   0.280    7.463      0.006      0.465         0.268          0.805
                   *F7[^\*^](#TN1){ref-type="table-fn"}*        −0.496   0.175    8.034      0.005      0.609         0.432          0.858
                   *FLT3[^\*^](#TN1){ref-type="table-fn"}*      −0.700   0.240    8.512      0.004      0.497         0.310          0.795
                   *G6PD*                                       0.477    0.188    6.438      0.011      1.611         1.115          2.328
                   *GNMT*                                       0.427    0.160    7.118      0.008      1.533         1.120          2.097
                   *ITGB2[^\*^](#TN1){ref-type="table-fn"}*     1.112    0.301    13.662     0.000      3.042         1.686          5.486
                   *KLRK1*                                      0.932    0.384    5.883      0.015      2.539         1.196          5.390
                   *KNG1[^\*^](#TN1){ref-type="table-fn"}*      0.645    0.277    5.412      0.020      1.906         1.107          3.282
                   *LMOD1[^\*^](#TN1){ref-type="table-fn"}*     −0.873   0.410    4.524      0.033      0.418         0.187          0.934
                   *NEK2*                                       −0.546   0.263    4.299      0.038      0.579         0.346          0.971
                   *PCLAF*                                      0.526    0.243    4.700      0.030      1.693         1.052          2.724
                   *PER1*                                       −0.670   0.221    9.169      0.002      0.512         0.332          0.790
                   *PKM*                                        −0.645   0.282    5.210      0.022      0.525         0.302          0.913
                   *POU2F1*                                     0.455    0.142    10.236     0.001      1.577         1.193          2.084
                   *PPAT[^\*^](#TN1){ref-type="table-fn"}*      0.966    0.210    21.121     0.000      2.628         1.741          3.969
                   *PPIA[^\*^](#TN1){ref-type="table-fn"}*      0.626    0.183    11.661     0.001      1.870         1.306          2.679
                   *PRF1[^\*^](#TN1){ref-type="table-fn"}*      −1.676   0.370    20.505     0.000      0.187         0.091          0.386
                   *PTPN6*                                      −0.610   0.227    7.203      0.007      0.543         0.348          0.848
                   *RUNX3*                                      0.967    0.375    6.659      0.010      2.629         1.262          5.479
                   *SELP[^\*^](#TN1){ref-type="table-fn"}*      0.790    0.270    8.587      0.003      2.203         1.299          3.736
                   *SLCO1B1*                                    −0.524   0.213    6.029      0.014      0.592         0.390          0.900
                   *SPPL2A[^\*^](#TN1){ref-type="table-fn"}*    −0.669   0.217    9.528      0.002      0.512         0.335          0.783
                   *STAT5A*                                     −1.704   0.489    12.149     0.000      0.182         0.070          0.474
                   *TCF21*                                      −0.979   0.401    5.961      0.015      0.376         0.171          0.824
                   *TRPV1[^\*^](#TN1){ref-type="table-fn"}*     −0.520   0.189    7.604      0.006      0.595         0.411          0.860
                   *TUSC1*                                      0.423    0.188    5.044      0.025      1.526         1.055          2.207
                   *TYMS*                                       0.523    0.245    4.558      0.033      1.687         1.044          2.727
  OS associated    *ABCC1*                                      1.097    0.369    8.841      0.003      2.994         1.453          6.168
                   *ANXA7[^\*^](#TN1){ref-type="table-fn"}*     −0.554   0.201    7.618      0.006      0.575         0.388          0.852
                   *APOB*                                       −0.791   0.311    6.461      0.011      0.453         0.246          0.834
                   *ATG7*                                       0.613    0.312    3.876      0.049      1.847         1.003          3.400
                   *BAK1*                                       −0.490   0.231    4.497      0.034      0.613         0.390          0.964
                   *CA9*                                        0.761    0.363    4.399      0.036      2.140         1.051          4.356
                   *CCNA2*                                      0.502    0.203    6.094      0.014      1.652         1.109          2.461
                   *CHD1L*                                      0.491    0.181    7.377      0.007      1.634         1.147          2.330
                   *CYP3A4*                                     0.999    0.364    7.539      0.006      2.717         1.331          5.544
                   *E2F1*                                       0.360    0.172    4.371      0.037      1.433         1.023          2.008
                   *EZH2*                                       0.985    0.399    6.103      0.013      2.678         1.226          5.852
                   *F2[^\*^](#TN1){ref-type="table-fn"}*        0.711    0.313    5.174      0.023      2.036         1.103          3.757
                   *G6PC*                                       −0.677   0.341    3.937      0.047      0.508         0.260          0.992
                   *GMPS*                                       0.733    0.291    6.345      0.012      2.081         1.177          3.681
                   *GOT2[^\*^](#TN1){ref-type="table-fn"}*      −1.509   0.484    9.723      0.002      0.221         0.086          0.571
                   *HDAC2*                                      0.813    0.316    6.628      0.010      2.255         1.214          4.187
                   *HPX[^\*^](#TN1){ref-type="table-fn"}*       0.930    0.384    5.882      0.015      2.535         1.195          5.378
                   *KPNA2*                                      0.835    0.284    8.664      0.003      2.305         1.322          4.018
                   *LAPTM4B*                                    −0.492   0.168    8.616      0.003      0.611         0.440          0.849
                   *MAGEB3[^\*^](#TN1){ref-type="table-fn"}*    0.393    0.179    4.824      0.028      1.482         1.043          2.105
                   *MAPT[^\*^](#TN1){ref-type="table-fn"}*      0.660    0.243    7.349      0.007      1.934         1.201          3.117
                   *MPV17[^\*^](#TN1){ref-type="table-fn"}*     1.141    0.488    5.468      0.019      3.129         1.203          8.141
                   *NTF3[^\*^](#TN1){ref-type="table-fn"}*      1.089    0.357    9.318      0.002      2.973         1.477          5.983
                   *PPAT[^\*^](#TN1){ref-type="table-fn"}*      0.752    0.286    6.897      0.009      2.122         1.210          3.719
                   *SLC2A1[^\*^](#TN1){ref-type="table-fn"}*    −0.921   0.440    4.383      0.036      0.398         0.168          0.943
                   *SLC38A1[^\*^](#TN1){ref-type="table-fn"}*   −0.768   0.289    7.063      0.008      0.464         0.263          0.817
                   *SPP1*                                       0.604    0.264    5.219      0.022      1.830         1.090          3.073
                   *TRPV1[^\*^](#TN1){ref-type="table-fn"}*     0.453    0.201    5.044      0.025      1.572         1.059          2.334

*The gene has not been systematically reported to be associated with HCC prognosis*.

*Cox proportional hazard model was used to analyze the impact of 135 genes on DFS and the impact of 149 genes on OS, respectively, P \< 0.05 were considered to be significant*.

*39 genes and 28 genes were significantly associated with liver cancer DFS and OS, respectively*.

The OS-related multivariate analysis results showed that the expression of 28 genes (*ABCC1, ANXA7, APOB, ATG7, BAK1, CA9, CCNA2, CHD1L, CYP3A4, E2F1, EZH2, F2, G6PC, GMPS, GOT2, HDAC2, HPX, KPNA2, LAPTM4B, MAGEB3, MAPT, MPV17, NTF3, PPAT, SLC2A1, SLC38A1, SPP1*, and *TRPV1*) was significantly associated with OS in HCC patients. (*p* \< 0.05, [Table 1](#T1){ref-type="table"}). The strongly significant results of both the OS-related single-gene survival analyses and multivariate analysis confirmed that these 28 genes are significantly associated with the OS of liver cancer, especially the 5-year survival rate of liver cancer.

Additionally, among the above-mentioned genes selected after single-gene survival analyses and multivariate analyses, 3 genes (*APOB, PPAT*, and *TRPV1*) were significantly associated with both DFS and OS in HCC patients.

Heat maps of the expression of the above 39 DFS-related genes and 28 OS-related genes in 1173 TCGA liver cancer samples, respectively, which grouped by prognosis status, were shown in [Supplementary Figure S1](#SM1){ref-type="supplementary-material"}.

Three-Gene-Combination Prognostic Model
---------------------------------------

To reflect the association of the expression of the combined genes with the prognosis of HCC, three-gene-combinations of the above 39 and 28 single genes that are significantly associated with DFS and OS, respectively, were formed, resulting in 9,139 and 3,276 three-gene-combinations for DFS and OS, respectively. In each combination, simultaneous high expression of the three genes in the same case was defined as the co-high expression group. Similarly, simultaneous low expression of the three genes in the same case was considered to be the co-low expression group. In order to ensure the comparability between the high and the low expression group, we deleted combinations which had \< 25 cases in the co-high or co-low expression group.

### Three-Gene-Combination of Prediction for DFS in Liver Cancer

K-M survival analysis of each of the above 9,139 combinations constituted by 39 DFS-related single genes was first performed. Then, we selected a total of 2,758 combinations with *p*-values \< 0.01, excluding the combinations with no more than 25 cases in the co-high expression or co-low expression groups. Apparently, these selected 2,758 combinations have significant prognostic implications for DFS in liver cancer.

In addition, 18 of the above 39 single genes have not yet been systematically reported to be associated with HCC prognosis, and these 18 genes can combine into 816 three-gene-combinations. The results of the K-M survival analyses showed that 317 combinations had significant association with DFS of liver cancer (*p* \< 0.01).

The top 15 combinations of the above 2,758 and 317 combinations with the smallest *p*-values were chosen. The DFS-related survival analyses diagrams and tables of these combinations and the single genes they contain are as follows ([Figures 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}; [Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}).

![Association of DFS and the top 15 three-gene-combinations with smallest *p-*values, using the data of HCC samples in a TCGA cohort and assessed by Kaplan-Meier analyses. The high expression group (blue line) of the combination consisted of samples with high expression of all three genes, and the low expression group (green line) of the combination consisted of samples with low expression of all three genes. The number of high and low expression groups in each combination was \>25. **(A)** Association of DFS and the top 15 combinations of the overall genes combinations. **(B)** Association of DFS and the top 15 combinations of the unreported genes combinations.](fonc-10-00847-g0002){#F2}

![Association of DFS and the individual genes contained in the top 15 combinations with the lowest *P*-values, using the data of HCC samples in a TCGA cohort and assessed by Kaplan-Meier analyses. **(A)** Association of DFS and the 17 single genes contained in the first 15 total-gene combinations. **(B)** Association of DFS and the 16 single genes contained in the first 15 unreported-gene combinations.](fonc-10-00847-g0003){#F3}

###### 

The associations of three-gene combinations with disease-free survival (DFS) of HCC patients in a TCGA cohort, analyzed by Kaplan-Meier method.

  **DFS (Median) of combinations of 39 genes with HCC prognosis**             **DFS (Median) of combinations of 18 genes have unknown association with HCC prognosis**                                                                                                                               
  ----------------------------------------------------------------- --------- ------------------------------------------------------------------------------------------ -------- -------- --------- ------- --------- -- ------------------- --------- -------- -------- -------- --------- ------- ---------
  *DNASE1-PPIA-TUSC1*                                               H         9.490                                                                                      1.597    6.360    12.620    0.000   −62.420      *CD4-F7-TRPV1*      H         71.910   20.619   31.498   112.322   0.000   65.010
                                                                    L         71.910                                                                                     24.365   24.154   119.666                                            L         6.900    1.657    3.652    10.148            
                                                                    Overall   21.620                                                                                     4.848    12.119   31.121                                             Overall   15.740   5.309    5.334    26.146            
  *CD4-F7-TRPV1*                                                    H         71.910                                                                                     20.619   31.498   112.322   0.000   65.010       *CD4-F7-LMOD1*      H         70.070   --       --       --        0.000   63.830
                                                                    L         6.900                                                                                      1.657    3.652    10.148                                             L         6.240    1.408    3.480    9.000             
                                                                    Overall   15.740                                                                                     5.309    5.334    26.146                                             Overall   17.640   3.833    10.127   25.153            
  *CD4-F7-GNMT*                                                     H         71.910                                                                                     22.303   28.196   115.624   0.000   63.370       *CD4-COL18A1-F7*    H         67.580   21.110   26.205   108.955   0.000   59.660
                                                                    L         8.540                                                                                      1.241    6.108    10.972                                             L         7.920    1.658    4.670    11.170            
                                                                    Overall   21.160                                                                                     4.039    13.244   29.076                                             Overall   19.190   3.616    12.104   26.276            
  *CD4-F7-LMOD1*                                                    H         70.070                                                                                     --       --       --        0.000   63.830       *CD4-FLT3-SPPL2A*   H         70.070   18.005   34.779   105.361   0.000   62.220
                                                                    L         6.240                                                                                      1.408    3.480    9.000                                              L         7.850    1.486    4.937    10.763            
                                                                    Overall   17.640                                                                                     3.833    10.127   25.153                                             Overall   19.650   7.275    5.391    33.909            
  *CD4-COL18A1-F7*                                                  H         67.580                                                                                     21.110   26.205   108.955   0.000   59.660       *C5-CD4-F7*         H         67.580   15.374   37.447   97.713    0.000   59.660
                                                                    L         7.920                                                                                      1.658    4.670    11.170                                             L         7.920    1.414    5.149    10.691            
                                                                    Overall   19.190                                                                                     3.616    12.104   26.276                                             Overall   21.160   5.704    9.981    32.339            
  *APOB-CD4-SLCO1B1*                                                H         66.620                                                                                     13.239   40.672   92.568    0.000   57.130       *CD4-F7-SELP*       H         71.910   3.184    65.669   78.151    0.000   63.200
                                                                    L         9.490                                                                                      0.918    7.691    11.289                                             L         8.710    0.783    7.176    10.244            
                                                                    Overall   19.650                                                                                     4.976    9.897    29.403                                             Overall   21.550   8.496    4.898    38.202            
  *CD4-CPT2-F7*                                                     H         71.910                                                                                     21.206   30.347   113.473   0.000   64.060       *CD4-F7-PRF1*       H         70.070   15.899   38.908   101.232   0.000   61.500
                                                                    L         7.850                                                                                      2.024    3.883    11.817                                             L         8.570    1.055    6.502    10.638            
                                                                    Overall   15.700                                                                                     2.776    10.259   21.141                                             Overall   21.160   3.455    14.389   27.931            
  *CD4-F7-PER1*                                                     H         70.070                                                                                     2.855    64.475   75.665    0.000   61.500       *CD4-SELP-SPPL2A*   H         70.070   3.849    62.525   77.615    0.000   61.500
                                                                    L         8.570                                                                                      1.225    6.170    10.970                                             L         8.570    0.819    6.964    10.176            
                                                                    Overall   25.300                                                                                     8.227    9.175    41.425                                             Overall   18.590   5.837    7.149    30.031            
  *APOB-CD4-SPPL2A*                                                 H         70.070                                                                                     23.928   23.171   116.969   0.000   60.940       *CD4-F7-FLT3*       H         70.070   3.048    64.097   76.043    0.000   61.360
                                                                    L         9.130                                                                                      0.855    7.455    10.805                                             L         8.710    1.311    6.140    11.280            
                                                                    Overall   19.190                                                                                     4.689    10.000   28.380                                             Overall   35.580   12.142   11.781   59.379            
  *CD4-FLT3-SPPL2A*                                                 H         70.070                                                                                     18.005   34.779   105.361   0.000   62.220       *CD4-F7-SPPL2A*     H         --       --       --       --        0.000   --
                                                                    L         7.850                                                                                      1.486    4.937    10.763                                             L         7.920    1.864    4.266    11.574            
                                                                    Overall   19.650                                                                                     7.275    5.391    33.909                                             Overall   24.770   19.276   0.000    62.551            
  *DNASE1-PPAT-TUSC1*                                               H         7.420                                                                                      1.115    5.235    9.605     0.000   −39.620      *DAND5-PPAT-PPIA*   H         8.540    0.797    6.978    10.102    0.000   −33.480
                                                                    L         47.040                                                                                     17.350   13.035   81.045                                             L         42.020   15.014   12.592   71.448            
                                                                    Overall   21.160                                                                                     5.101    11.162   31.158                                             Overall   19.250   2.763    13.834   24.666            
  *APOB-CD4-F7*                                                     H         67.580                                                                                     13.500   41.120   94.040    0.000   58.840       *CD4-CETP-KNG1*     H         50.030   14.498   21.614   78.446    0.000   41.550
                                                                    L         8.740                                                                                      0.884    7.007    10.473                                             L         8.480    0.769    6.972    9.988             
                                                                    Overall   24.770                                                                                     9.057    7.018    42.522                                             Overall   18.330   1.894    14.617   22.043            
  *CD4-SLCO1B1-SPPL2A*                                              H         71.910                                                                                     --       --       --        0.000   62.420       *C5-F7-ITGB2*       H         67.580   14.028   40.084   95.076    0.000   59.010
                                                                    L         9.490                                                                                      1.171    7.194    11.786                                             L         8.570    1.316    5.991    11.149            
                                                                    Overall   19.650                                                                                     6.519    6.873    32.427                                             Overall   35.580   9.185    17.577   53.583            
  *C5-CD4-F7*                                                       H         67.580                                                                                     15.374   37.447   97.713    0.000   59.660       *CD4-F7-KNG1*       H         --       --       --       --        0.000   --
                                                                    L         7.920                                                                                      1.414    5.149    10.691                                             L         8.740    1.206    6.376    11.104            
                                                                    Overall   21.160                                                                                     5.704    9.981    32.339                                             Overall   21.550   8.293    5.295    37.805            
  *CD4-GNMT-LMOD1*                                                  H         50.030                                                                                     16.348   17.987   82.073    0.000   41.550       *CD4-CETP-SELP*     H         66.620   14.883   37.450   95.790    0.000   56.370
                                                                    L         8.480                                                                                      1.430    5.677    11.283                                             L         10.250   1.315    7.672    12.828            
                                                                    Overall   18.330                                                                                     2.734    12.971   23.689                                             Overall   18.330   1.469    15.452   21.208            

###### 

The associations of single genes contained in the multi-gene combinations with disease-free survival (DFS) and overall survival (OS) of HCC patients in a TCGA cohort, analyzed by Kaplan-Meier method.

  **DFS (Median) of single genes of the combinations with HCC prognosis**             **OS (Median) of single genes of the combinations with HCC prognosis**                                                                                                                      
  ------------------------------------------------------------------------- --------- ------------------------------------------------------------------------ -------- -------- -------- ------- --------- -- ----------- --------- -------- -------- -------- --------- ------- ---------
  *APOB*                                                                    H         29.300                                                                   6.376    16.802   41.798   0.008   14.450       *ANXA7*     H         83.180   15.496   52.807   113.553   0.006   36.430
                                                                            L         14.850                                                                   2.049    10.834   18.866                                    L         46.750   7.280    32.481   61.019            
                                                                            Overall   20.930                                                                   2.318    16.387   25.473                                    Overall   55.650   7.925    40.116   71.184            
  *C5*                                                                      H         29.960                                                                   6.762    16.706   43.214   0.001   16.330       *ATG7*      H         45.070   8.031    29.330   60.810    0.009   −35.610
                                                                            L         13.630                                                                   2.870    8.006    19.254                                    L         80.680   10.533   60.036   101.324           
                                                                            Overall   20.930                                                                   2.318    16.387   25.473                                    Overall   55.650   7.925    40.116   71.184            
  *CD4*                                                                     H         36.700                                                                   7.693    21.622   51.778   0.000   23.070       *CA9*       H         37.290   8.317    20.989   53.591    0.000   −32.720
                                                                            L         13.630                                                                   2.089    9.536    17.724                                    L         70.010   10.210   49.999   90.021            
                                                                            Overall   20.930                                                                   2.318    16.387   25.473                                    Overall   55.650   7.925    40.116   71.184            
  *CETP*                                                                    H         35.580                                                                   5.896    24.023   47.137   0.002   21.450       *CCNA2*     H         45.070   10.298   24.885   65.255    0.001   −24.940
                                                                            L         14.130                                                                   1.799    10.605   17.655                                    L         70.010   11.730   47.019   93.001            
                                                                            Overall   20.930                                                                   2.318    16.387   25.473                                    Overall   55.650   7.925    40.116   71.184            
  *COL18A1*                                                                 H         27.200                                                                   4.885    17.625   36.775   0.005   11.600       *CHD1L*     H         39.750   6.940    26.148   53.352    0.006   −40.930
                                                                            L         15.600                                                                   3.114    9.497    21.703                                    L         80.680   6.587    67.770   93.590            
                                                                            Overall   20.930                                                                   2.318    16.387   25.473                                    Overall   55.650   7.925    40.116   71.184            
  *CPT2*                                                                    H         29.300                                                                   4.767    19.956   38.644   0.005   14.350       *EZH2*      H         37.290   10.181   17.335   57.245    0.000   −43.390
                                                                            L         14.950                                                                   1.836    11.352   18.548                                    L         80.680   10.816   59.480   101.880           
                                                                            Overall   20.930                                                                   2.318    16.387   25.473                                    Overall   55.650   7.925    40.116   71.184            
  *DAND5*                                                                   H         13.630                                                                   2.561    8.610    18.650   0.001   −16.330      *F2*        H         69.510   11.842   46.300   92.720    0.005   23.620
                                                                            L         29.960                                                                   5.455    19.269   40.651                                    L         45.890   7.020    32.132   59.648            
                                                                            Overall   20.930                                                                   2.318    16.387   25.473                                    Overall   55.650   7.925    40.116   71.184            
  *DNASE1*                                                                  H         13.140                                                                   1.997    9.226    17.054   0.001   −16.160      *GMPS*      H         45.070   9.667    26.123   64.017    0.003   −24.440
                                                                            L         29.300                                                                   4.256    20.958   37.642                                    L         69.510   10.308   49.306   89.714            
                                                                            Overall   20.930                                                                   2.318    16.387   25.473                                    Overall   55.650   7.925    40.116   71.184            
  *F7*                                                                      H         33.900                                                                   8.191    17.846   49.954   0.000   18.490       *GOT2*      H         70.010   12.025   46.441   93.579    0.000   32.260
                                                                            L         15.410                                                                   1.485    12.500   18.320                                    L         37.750   9.383    19.360   56.140            
                                                                            Overall   20.930                                                                   2.318    16.387   25.473                                    Overall   55.650   7.925    40.116   71.184            
  *FLT3*                                                                    H         35.580                                                                   3.640    28.446   42.714   0.000   22.440       *HPX*       H         69.510   10.518   48.894   90.126    0.002   23.620
                                                                            L         13.140                                                                   1.833    9.547    16.733                                    L         45.890   10.112   26.070   65.710            
                                                                            Overall   20.930                                                                   2.318    16.387   25.473                                    Overall   55.650   7.925    40.116   71.184            
  *GNMT*                                                                    H         29.300                                                                   9.167    11.334   47.266   0.002   13.370       *HDAC2*     H         45.070   8.365    28.675   61.465    0.002   −35.610
                                                                            L         15.930                                                                   1.821    12.360   19.500                                    L         80.680   12.796   55.599   105.761           
                                                                            Overall   20.930                                                                   2.318    16.387   25.473                                    Overall   55.650   7.925    40.116   71.184            
  *ITGB2*                                                                   H         35.580                                                                   4.232    27.285   43.875   0.002   19.840       *KPNA2*     H         33.020   8.165    17.017   49.023    0.000   −47.660
                                                                            L         15.740                                                                   2.671    10.504   20.976                                    L         80.680   6.908    67.139   94.221            
                                                                            Overall   20.930                                                                   2.318    16.387   25.473                                    Overall   55.650   7.925    40.116   71.184            
  *KNG1*                                                                    H         25.300                                                                   6.478    12.603   37.997   0.007   9.600        *LAPTM4B*   H         45.070   10.511   24.468   65.672    0.000   −35.610
                                                                            L         15.700                                                                   2.458    10.882   20.518                                    L         80.680   12.598   55.988   105.372           
                                                                            Overall   20.930                                                                   2.318    16.387   25.473                                    Overall   55.650   7.925    40.116   71.184            
  *LMOD1*                                                                   H         29.660                                                                   5.120    19.625   39.695   0.004   13.960       *MAPT*      H         41.750   6.888    28.249   55.251    0.006   −28.260
                                                                            L         15.700                                                                   2.655    10.497   20.903                                    L         70.010   9.844    50.716   89.304            
                                                                            Overall   20.930                                                                   2.318    16.387   25.473                                    Overall   55.650   7.925    40.116   71.184            
  *PER1*                                                                    H         25.490                                                                   6.529    12.694   38.286   0.003   10.080       *MPV17*     H         37.290   6.644    24.268   50.312    0.000   −43.390
                                                                            L         15.410                                                                   3.485    8.579    22.241                                    L         80.680   6.504    67.933   93.427            
                                                                            Overall   20.930                                                                   2.318    16.387   25.473                                    Overall   55.650   7.925    40.116   71.184            
  *PPAT*                                                                    H         14.130                                                                   2.656    8.924    19.336   0.000   −19.770      *NTF3*      H         70.010   12.704   45.110   94.910    0.002   29.640
                                                                            L         33.900                                                                   5.401    23.314   44.486                                    L         40.370   8.143    24.409   56.331            
                                                                            Overall   20.930                                                                   2.318    16.387   25.473                                    Overall   55.650   7.925    40.116   71.184            
  *PPIA*                                                                    H         15.600                                                                   1.475    12.709   18.491   0.000   −13.280      *PPAT*      H         58.840   14.928   29.580   88.100    0.009   −10.670
                                                                            L         28.880                                                                   7.575    14.033   43.727                                    L         69.510   11.354   47.256   91.764            
                                                                            Overall   20.930                                                                   2.318    16.387   25.473                                    Overall   55.650   7.925    40.116   71.184            
  *PRF1*                                                                    H         29.960                                                                   4.358    21.418   38.502   0.000   17.350       *SLC2A1*    H         45.890   6.187    33.763   58.017    0.000   −37.290
                                                                            L         12.610                                                                   2.004    8.681    16.539                                    L         83.180   17.113   49.638   116.722           
                                                                            Overall   20.930                                                                   2.318    16.387   25.473                                    Overall   55.650   7.925    40.116   71.184            
  *SELP*                                                                    H         29.960                                                                   6.294    17.624   42.296   0.001   14.260       *SLC38A1*   H         45.070   3.919    37.389   52.751    0.001   −35.610
                                                                            L         15.700                                                                   2.465    10.868   20.532                                    L         80.680   7.141    66.684   94.676            
                                                                            Overall   20.930                                                                   2.318    16.387   25.473                                    Overall   55.650   7.925    40.116   71.184            
  *SLCO1B1*                                                                 H         35.840                                                                   10.368   15.518   56.162   0.000   20.890       *SPP1*      H         40.370   5.288    30.005   50.735    0.000   −29.640
                                                                            L         14.950                                                                   1.359    12.286   17.614                                    L         70.010   13.016   44.498   95.522            
                                                                            Overall   20.930                                                                   2.318    16.387   25.473                                    Overall   55.650   7.925    40.116   71.184            
  *SPPL2A*                                                                  H         27.200                                                                   5.000    17.399   37.001   0.005   11.790       *TRPV1*     H         80.680   7.672    65.642   95.718    0.002   35.610
                                                                            L         15.410                                                                   2.331    10.842   19.978                                    L         45.070   6.030    33.250   56.890            
                                                                            Overall   20.930                                                                   2.318    16.387   25.473                                    Overall   55.650   7.925    40.116   71.184            
  *TRPV1*                                                                   H         29.660                                                                   6.127    17.652   41.668   0.005   13.530                                                                          
                                                                            L         16.130                                                                   1.962    12.284   19.976                                                                                           
                                                                            Overall   20.930                                                                   2.318    16.387   25.473                                                                                           
  *TUSC1*                                                                   H         15.740                                                                   2.003    11.814   19.666   0.001   −18.160                                                                         
                                                                            L         33.900                                                                   8.193    17.841   49.959                                                                                           
                                                                            Overall   20.930                                                                   2.318    16.387   25.473                                                                                           

### Three-Gene-Combination of Prediction for OS in Liver Cancer

Similarly, three-gene-combinations of the 28 single genes significantly associated with OS confirmed by the single gene survival analyses and the multivariate analysis were formed, resulting in 3,276 three-gene-combinations. 930 of these 3,276 combinations were screened out on the conditions that the number of cases in both the co-high and co-low expression groups was \> 25, and the *p*-values were \< 0.01 according to the OS-related K-M analyses results.

Furthermore, 12 of the above 28 single genes that were noted to have an unknown association with liver cancer prognosis formed 220 three-gene-combinations. Out of the 220 combinations, there were 31 combinations in which the number of cases in both the co-high and co-low expression groups was \> 25 and the OS-related survival analyses results showed *p* \< 0.01.

We found 930 of above 3,276 combinations and 31 of above 220 unreported-gene combinations were significant association with OS related survival of liver cancer patients. Among the 930 combinations and 31 combinations mentioned above, the diagrams and tables of the OS-related survival analyses of the top 15 combinations with the smallest *p*-values and the single genes they contain are as follows ([Figures 4](#F4){ref-type="fig"}, [5](#F5){ref-type="fig"}; [Tables 3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}) Among the 12 genes that have an unknown association with HCC prognosis, *F2, GOT2, TRPV1*, and their combination *F2-GOT2-TRPV1* were all significantly associated with OS in 370 liver cancer samples from the TCGA data (*F2*: *p* = 0.005; *GOT2*: *p* \< 0.001; *TRPV1*: *p* = 0.002; *F2-GOT2-TRPV1*: *p* \< 0.001). The overall survival rate in HCC patients with low expression of *F2, GOT2, TRPV1*, and the three-gene-combination *F2*-*GOT2*-*TRPV1* were all significantly lower than that in liver cancer patients with high expression. In addition, the median survival time difference between the high expression group and the low expression group of *F2, GOT2, TRPV1*, and the three-gene combination *F2*-*GOT2*-*TRPV1* was 23.62, 32.26, 35.61, and 55.68 months, respectively. The median survival time difference of this combination was greater than that of a single gene, which was one of the main reasons why we selected these three genes for qRT-PCR and immunohistochemically validation.

![Association of the top 15 three-gene-combinations with smallest *p*-values with OS, using the data of HCC samples in a TCGA cohort and assessed by Kaplan-Meier analyses. The high expression group (blue line) of the combination consisted of samples with high expression of all three genes, and the low expression group (green line) of the combination consisted of samples with low expression of all three genes. The number of high and low expression groups in each combination was \>25. **(A)** Association of OS and the top 15 combinations with the smallest *p*-values of the overall genes combinations. **(B)** Association of OS and the top 15 combinations with the smallest *p*-values of the unreported genes combinations.](fonc-10-00847-g0004){#F4}

![Association of OS and the individual genes contained in the top 15 combinations with the lowest *P*-values, using the data of HCC samples in a TCGA cohort and assessed by Kaplan-Meier analyses. **(A)** Association of OS and the 14 single genes contained in the first 15 total-gene combinations. **(B)** Association of OS and the 11 single genes contained in the first 15 unreported-gene combinations.](fonc-10-00847-g0005){#F5}

###### 

The associations of three-gene combinations with overall survival (OS) of HCC patients in a TCGA cohort, analyzed by Kaplan-Meier method.

  **OS (Median) of combinations of 28 genes with HCC prognosis**             **OS (Median) of combinations of 12 genes have unknown association with HCC prognosis**                                                                                                                                    
  ---------------------------------------------------------------- --------- ----------------------------------------------------------------------------------------- -------- -------- --------- ------- --------- -- ------------------------ --------- -------- -------- -------- --------- ------- ---------
  *EZH2-KPNA2-MPV17*                                               H         21.320                                                                                    6.143    9.280    33.360    0.000   −59.360      *GOT2-NTF3-TRPV1*        H         --       --       --       --        0.000   --
                                                                   L         80.680                                                                                    7.061    66.841   94.519                                                  L         25.230   3.764    17.852   32.608            
                                                                   Overall   55.350                                                                                    13.443   29.001   81.699                                                  Overall   60.840   15.622   30.220   91.460            
  *EZH2-LAPTM4B-MPV17*                                             H         18.230                                                                                    5.735    6.988    29.472    0.000   −62.450      *MPV17-PPAT-SLC2A1*      H         18.330   4.916    8.695    27.965    0.000   −64.850
                                                                   L         80.680                                                                                    7.990    65.020   96.340                                                  L         83.180   15.794   52.224   114.136           
                                                                   Overall   48.950                                                                                    10.014   29.323   68.577                                                  Overall   53.350   15.422   23.123   83.577            
  *CA9-KPNA2-SPP1*                                                 H         23.780                                                                                    5.368    13.259   34.301    0.000   −59.400      *MPV17-SLC2A1-SLC38A1*   H         25.130   9.272    6.957    43.303    0.000   −58.050
                                                                   L         83.180                                                                                    16.292   51.248   115.112                                                 L         83.180   7.322    68.829   97.531            
                                                                   Overall   51.250                                                                                    11.668   28.381   74.119                                                  Overall   46.750   6.571    33.870   59.630            
  *CA9-KPNA2-LAPTM4B*                                              H         19.740                                                                                    3.699    12.490   26.990    0.000   −63.440      *GOT2-HPX-NTF3*          H         70.010   10.631   49.174   90.846    0.000   50.430
                                                                   L         83.180                                                                                    20.669   42.669   123.691                                                 L         19.580   6.243    7.343    31.817            
                                                                   Overall   46.750                                                                                    6.141    34.715   58.785                                                  Overall   55.350   6.783    42.055   68.645            
  *KPNA2-SLC38A1-SPP1*                                             H         19.090                                                                                    6.876    5.614    32.566    0.000   −83.570      *MAPT-SLC2A1-SLC38A1*    H         25.130   9.134    7.227    43.033    0.000   −58.050
                                                                   L         102.660                                                                                   21.958   59.622   145.698                                                 L         83.180   12.085   59.493   106.867           
                                                                   Overall   69.510                                                                                    10.951   48.047   90.973                                                  Overall   45.890   7.002    32.167   59.613            
  *HDAC2-KPNA2-SPP1*                                               H         23.780                                                                                    5.613    12.778   34.782    0.000   −78.880      *MAPT-MPV17-SLC38A1*     H         25.130   4.047    17.197   33.063    0.000   −58.050
                                                                   L         102.660                                                                                   14.189   74.850   130.470                                                 L         83.180   9.720    64.128   102.232           
                                                                   Overall   83.180                                                                                    21.672   40.704   125.656                                                 Overall   45.070   6.284    32.754   57.386            
  *CHD1L-EZH2-SPP1*                                                H         15.410                                                                                    4.012    7.547    23.273    0.000   −67.770      *GOT2-HPX-TRPV1*         H         83.180   11.770   60.111   106.249   0.000   50.160
                                                                   L         83.180                                                                                    9.866    63.842   102.518                                                 L         33.020   6.971    19.356   46.684            
                                                                   Overall   46.750                                                                                    12.305   22.633   70.867                                                  Overall   70.010   14.673   41.251   98.769            
  *EZH2-KPNA2-LAPTM4B*                                             H         21.680                                                                                    5.445    11.008   32.352    0.000   −59.000      *ANXA7-F2-NTF3*          H         83.510   15.702   52.734   114.286   0.000   58.640
                                                                   L         80.680                                                                                    7.011    66.939   94.421                                                  L         24.870   10.561   4.170    45.570            
                                                                   Overall   46.750                                                                                    10.389   26.388   67.112                                                  Overall   53.350   14.230   25.459   81.241            
  *KPNA2-MPV17-SLC38A1*                                            H         17.580                                                                                    5.820    6.172    28.988    0.000   −63.100      *ANXA7-GOT2-NTF3*        H         83.180   23.271   37.569   128.791   0.000   62.580
                                                                   L         80.680                                                                                    7.992    65.015   96.345                                                  L         20.600   5.417    9.983    31.217            
                                                                   Overall   53.350                                                                                    11.888   30.049   76.651                                                  Overall   48.950   7.670    33.916   63.984            
  *ATG7-KPNA2-PPAT*                                                H         21.120                                                                                    6.087    9.190    33.050    0.000   −59.560      *ANXA7-GOT2-HPX*         H         83.180   13.677   56.373   109.987   0.000   58.310
                                                                   L         80.680                                                                                    10.953   59.212   102.148                                                 L         24.870   8.505    8.200    41.540            
                                                                   Overall   45.530                                                                                    11.839   22.325   68.735                                                  Overall   53.290   13.890   26.066   80.514            
  *GMPS-LAPTM4B-SLC2A1*                                            H         17.970                                                                                    6.680    4.876    31.064    0.000   −65.210      *MAPT-PPAT-SLC2A1*       H         20.110   6.433    7.501    32.719    0.000   −63.070
                                                                   L         83.180                                                                                    16.018   51.784   114.576                                                 L         83.180   14.580   54.602   111.758           
                                                                   Overall   53.350                                                                                    13.670   26.557   80.143                                                  Overall   70.010   18.751   33.258   106.762           
  *CHD1L-LAPTM4B-MPV17*                                            H         24.870                                                                                    4.882    15.302   34.438    0.000   −55.810      *F2-GOT2-TRPV1*          H         83.180   11.976   59.707   106.653   0.000   55.680
                                                                   L         80.680                                                                                    7.912    65.172   96.188                                                  L         27.500   6.805    14.162   40.838            
                                                                   Overall   55.650                                                                                    10.709   34.660   76.640                                                  Overall   81.670   20.419   41.649   121.691           
  *ATG7-GMPS-PPAT*                                                 H         13.960                                                                                    4.451    5.236    22.684    0.000   −66.720      *F2-GOT2-HPX*            H         83.180   6.650    70.146   96.214    0.000   45.890
                                                                   L         80.680                                                                                    17.665   46.057   115.303                                                 L         37.290   7.225    23.129   51.451            
                                                                   Overall   37.680                                                                                    8.510    21.001   54.359                                                  Overall   69.510   12.170   45.657   93.363            
  *CCNA2-LAPTM4B-MPV17*                                            H         18.330                                                                                    3.559    11.354   25.306    0.000   −51.680      *MPV17-PPAT-SLC38A1*     H         20.600   5.930    8.977    32.223    0.000   −60.080
                                                                   L         70.010                                                                                    6.190    57.878   82.142                                                  L         80.680   9.365    62.324   99.036            
                                                                   Overall   48.950                                                                                    7.272    34.697   63.203                                                  Overall   51.250   13.888   24.030   78.470            
  *KPNA2-LAPTM4B-MPV17*                                            H         21.320                                                                                    5.082    11.359   31.281    0.000   −59.360      *ANXA7-HPX-NTF3*         H         83.180   26.573   31.096   135.264   0.000   58.310
                                                                   L         80.680                                                                                    7.900    65.196   96.164                                                  L         24.870   7.244    10.672   39.068            
                                                                   Overall   51.250                                                                                    14.898   22.050   80.450                                                  Overall   48.950   5.919    37.350   60.550            

Low Expression of *F2, GOT2*, and *TRPV1* Predicts Poor Prognosis
-----------------------------------------------------------------

Based on the above results of the OS-related survival analyses and multivariate analyses on 28 genes, as well as the results of survival analyses on their three-gene-combinations, we selected three genes *F2, GOT2*, and *TRPV1* with strong liver cancer prognostic potential for subsequent validation.

### *F2, GOT2*, and *TRPV1* Were Downregulated in HCC Tissues

The gene expression in HCC was determined based on three independent microarrays which are all collected in Oncomine database (<https://www.oncomine.org/resource/login.html>). As shown in Roessler Liver 2 Statistics (225 HCC tissues vs. 220 liver tissues), the expression of *F2, GOT2*, and *TRPV1* in HCC tissues were all significantly down-regulated compared with that in normal liver tissues. (*p* \< 0.001; [Figure 6](#F6){ref-type="fig"}) In addition, based on the Mas Liver Statistics (38 HCC tissue vs. 19 liver tissue), both *F2* and *TRPV1* were significantly down-regulated in HCC tissues. Based on the Chen Liver Statistics (104 HCC tissues vs. 76 liver tissues), both *F2* and *GOT2* were significantly down-regulated in HCC tissues.

![Expression of *F2, GOT2*, and *TRPV1* in HCC and adjacent normal liver tissues confirmed by independent microarrays from the Oncomine database. The expression of **(A)** *F2*, **(B)** *GOT2*, and **(C)** *TRPV1* were all significantly reduced in HCC tissues by the Roessler Liver 2 Statistics \[225 HCC tissues (dark blue) vs. 220 normal liver tissues (light blue)\]. \*\*\**p* \< 0.001.](fonc-10-00847-g0006){#F6}

The qRT-PCR results of *F2, GOT2* and *TRPV1* showed that 20/20, 19/20, and 16/19 of the HCC tissues exhibited significantly lower expression of *F2* (*p* \< 0.001; [Figure 7A](#F7){ref-type="fig"})*, GOT2* (*p* \< 0.001; [Figure 7B](#F7){ref-type="fig"}), and *TRPV1* (*p* = 0.006; [Figure 7C](#F7){ref-type="fig"}), respectively, when compared with their corresponding non-tumorous tissues.

![The relative expression levels of *F2, GOT2*, and *TRPV1* were assessed by qRT-PCR in HCC tissues and adjacent liver tissues. **(A)** The expression levels of *F2* were assessed by qRT-PCR in 20 pairs of HCC tissues and peritumoral tissues. Paired *t*-test, \*\*\**p* \< 0.001. **(B)** The relative expression levels of *GOT2* were assessed by qRT-PCR in 19 pairs of HCC tissues and peritumoral tissues. Paired *t*-test, \*\*\**p* \< 0.001. **(C)** The relative expression levels of *TRPV1* were assessed by qRT-PCR in 19 pairs of HCC tissues and peritumoral tissues. Paired *t*-test, log, \*\**p* \< 0.01.](fonc-10-00847-g0007){#F7}

The protein expression of *F2, GOT2*, and *TRPV1* in HCC tissues was evaluated using IHC. Positive staining of *F2, GOT2*, and *TRPV1* was mainly localized in the cytoplasm of HCC cells. The representative staining of *F2, GOT2*, and *TRPV1* negative and positive protein expression in HCC are shown in [Figure 8A](#F8){ref-type="fig"}.

![The expression of *F2, GOT2*, and *TRPV1* in 90 pairs of HCC and adjacent normal liver tissues of biological tissue microarray by IHC, and the association with HCC patients prognosis. **(A)** Negative, weakly positive, intermediately positive, and strongly positive IHC staining of *F2, GOT2*, and *TRPV1*. *F2, GOT2*, and *TRPV1* were all low expressed in liver cancer. **(B)** The lower protein expression levels of *F2, GOT2*, and *TRPV1* were all associated with 5-year OS of 90 HCC patients, examing by Kaplan-Meier analyses and log-rank test. However, there was marginally significant association between the *F2*-*GOT2*-*TRPV1* combination protein expression levels with the OS of HCC patients. (*F2*: *p* = 0.033, *GOT2*: *p* = 0.035, *TRPV1*: *p* = 0.046, *F2*-*GOT2*-*TRPV1: p* = 0.051).](fonc-10-00847-g0008){#F8}

Among 90 HCC tissues and adjacent non-malignant liver tissues, IHC was employed to measure the protein expression of *F2, GOT2*, and *TRPV1*, respectively. Low *F2* expression was observed in 62/89 (69.66%) of the HCC tissues, compared to 33/89 (37.08%) in adjacent normal liver tissues (*p* \< 0.001); low *GOT2* expression was noted in 72/89 (80.90%) of the HCC tissues, compared to 32/89 (35.96%) in adjacent normal liver tissues (*p* \< 0.001); low *TRPV1* expression was also observed in 59/89 (66.29%) of the HCC tissues, compared to 38/89 (42.70%) in adjacent normal liver tissues (*p* = 0.002).

### Expression of *F2, GOT2*, and *TRPV1* and Their Combination *F2-GOT2-TRPV1* With OS

Based on the above results of single-genes and three-gene combinations survival analyses of TCGA HCC samples, the low expression of *F2, GOT2, TRPV1* and their combination *F2-GOT2-TRPV1* was significantly associated with poor OS in HCC. (*F2*: *p* = 0.005; *GOT2*: *p* \< 0.001; *TRPV1*: *p* = 0.002; *F2-GOT2-TRPV1*: *p* \< 0.001). In addition, the median survival time difference between the high expression group and the low expression group of *F2*-*GOT2*-*TRPV1* was greater than that of any of the three single genes.

The results of IHC for 90 liver cancer cases showed that the low protein expression of *F2, GOT2*, and *TRPV1* was significantly associated with lower 5-year survival in HCC patients (*F2*: *p* = 0.033, *GOT2*: *p* = 0.035, *TRPV1*: *p* = 0.046; K-M survival analyses). However, due to the insufficient number of events in the co-high expression group of the combination *F2-GOT2-TRPV1*, there was marginally significant difference found in the overall survival rate of HCC patients between the co-high expression group and the co-low expression group of the protein combination *F2-GOT2-TRPV1* (*p* = 0.051) ([Figure 8B](#F8){ref-type="fig"}).

Discussion {#s4}
==========

Liver cancer is characterized by inconspicuous early symptoms, a high degree of malignancy, recurrence and spread, and unsatisfactory prognosis. With limited treatment options, it is one of the common malignancies that plague the world. Therefore, identification of effective prognostic biomarkers for liver cancer is the key to improving the efficacy of targeted therapy for HCC and reducing the adverse prognostic effects of liver cancer.

In our study, by combining and searching 15 corresponding concepts of the key words "liver cancer," "prognosis," and "outcome," and according to *p*-values \< 0.05, 1,173 genes that may be related to the prognosis of liver cancer were mined from the Coremine platform after merging and removing duplicates. However, due to the insufficient sample size and data related to the prognosis of liver cancer in the Coremine platform as well as the large heterogeneity among the samples, we also selected gene expression data and prognosis data of 319 samples for DFS and 370 samples for OS from the TCGA platform. We then separately conducted DFS-related and OS-related K-M survival analysis for each gene, followed by multivariate analyses, respectively. The large-scale genes mining and a large number of homogenous samples gave us a reliable analytical foundation. By far, this is the first large-scale survival analyses for hundreds of genes for subsequent screening.

In addition, the genes selected by K-M survival analyses with a low *p*-value (*p* \< 0.01) were further screened by multivariate analyses using the Cox proportional hazards regression model. We found that 39 genes and 28 genes were reliably and significantly associated with DFS and OS, respectively, in liver cancer. Many of the above genes have been confirmed to be associated with the prognosis of HCC by previous reports. For example, of the 39 DFS-related genes, *ALDOB* inhibits metastasis in HCC and can be a valuable novel prognosis predicting marker ([@B30]); *APOB* was found to be a prognostic biomarker for patients with radical resection of HCC ([@B31], [@B32]); *CCNF* is downregulated in HCC and is a promising prognostic marker ([@B33]). In addition, *CPT2* ([@B34]), *G6PD* ([@B35]), *GNMT* ([@B36]), *NEK2* ([@B37]), etc. have also been reported to be prognostic markers of HCC by affecting the occurrence or invasion of HCC. The above findings are consistent with what we identified. Other genes, such as *C5, CD4, CETP, COL18A1, DAND5, DNASE1, EBPL, F7, FLT3, ITGB2, KNG1, LMOD1, PPAT, PPIA, PRF1, SELP, SPPL2A*, and *TRPV1* that have not been systematically reported in relation to the prognosis of liver cancer, are our newly discovered prognostic markers for DFS in liver cancer. Similarly, of the 28 OS-related genes, *CA9* regulates the epithelial-mesenchymal transition and is a novel prognostic marker in HCC ([@B38]), *E2F1* expression has an impact on tumor aggressiveness and affects the prognosis of HCC ([@B14], [@B15]), *CYP3A4* ([@B39]), *HDAC2* ([@B40]), and *KPNA2* ([@B41]) have also been identified as prognostic markers of HCC and are reflected in our findings. The other genes, such as *ANXA7, F2, GOT2, HPX, MAGEB3, MAPT, MPV17, NTF3, PPAT, SLC2A1, SLC38A1*, and *TRPV1* are all novel prognostic markers associated with liver cancer OS found by our reliable and large-scale screening studies. Three genes (*APOB, PPAT*, and *TRPV1*) were associated with both DFS and OS of HCC, suggesting that *APOB, PPAT*, and *TRPV1* may be significant and effective in predicting both the progress and the adverse outcomes of HCC.

Moreover, there may be connections among the above selected genes and they can work together to influence the development and prognosis of liver cancer to some extent. Although there are some genes that had been reported as prognostic molecular markers of liver cancer, most reports focused on the impact of a single gene on the prognosis of liver cancer, few studies performed such a large-scale survival analysis. Studies of multiple gene combinations are more effective than the analysis of single genes in predicting the prognosis of liver cancer.

In our study, we performed three-gene combinations of the 39 DFS-related genes and 28 OS-related genes screened from the above survival analyses. In order to further study the predictive effect of the combinations constituted by the selected genes on the prognosis of liver cancer, and to compare the predictive power of single genes and corresponding gene combinations, we carried out thousands of K-M survival analyses on these combinations. To ensure the comparability and credibility, we removed the combinations of which the co-high or co-low expression group cases were fewer than 26, and screened 2,758 DFS-related combinations and 930 OS-related combinations with *p*-values \< 0.01. Moreover, we also performed three-gene-combination models and K-M survival analyses on the 18 DFS-related genes and 12 OS-related genes we found but have not been systematically reported to be related to the prognosis of HCC. 317 unreported-gene combinations and 31 unreported-gene combinations significantly associated with DFS and OS, respectively, were screened out.

For the above four types of three-gene-combinations (the overall genes combinations associated with DFS, the unreported genes combinations associated with DFS, the overall genes combinations associated with OS, and the unreported genes combinations associated with OS), the top 15 combinations with the lowest *p*-values of the survival analyses and the genes they contained were, respectively, selected for comparison ([Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}).

For example, for the overall gene combinations associated with OS, *KPNA2-SLC38A1-SPP1*, the median survival time difference between the co-high and the co-low expression group was 83.57 months. In contrast, that of the single genes *KPNA2, SLC38A1*, and *SPP1*, was 47.66, 35.61, and 29.64 months, respectively. After combining *KPNA2, SLC38A1*, and *SPP1*, the median survival time difference between the high and low expression groups was larger than that of any of the three single genes by at least 36 months. This shows that these three genes *KPNA2, SLC38A1*, and *SPP1*, after combination, may be better predictive values for liver cancer prognosis and may be more clinically useful for future treatment target selection.

We also selected genes that have not been previously reported for liver cancer prognosis and compared their prognostic efficacy with the corresponding three-gene combinations (the chart only shows the top 15 groups with the lowest *p*-values of the three-gene combinations prognostic models). The expression of one of the combinations *F2-GOT2-TRPV1* had a greater effect on the median survival time of OS than any of the three individual genes (The median survival time difference: *F2-GOT2-TRPV1*: 55.68 months; *F2*: 23.62 months; *GOT2*: 32.26 months; *TRPV1*: 35.61 months).

Coagulation factor II (*F2*) plays a major role in proteolysis to form thrombin in the first step of the coagulation cascade and eventually generates hemostasis. An enrichment analysis of genetic changes during the development of HCC identified several hub genes, including *F2*, which interacts in several groups of conditional specific PPI networks ([@B42]). Additionally, it was reported that *F2* is associated with invasion in neuroendocrine prostate cancer ([@B43]). Glutamic-oxaloacetic transaminase 2 (*GOT2*) plays an important role in amino acid metabolism and the tricarboxylic acid cycle, and it affects the malate-aspartic acid shuttle activity and glycolysis in the liver under the stimulation of liver inflammation. ([@B44], [@B45]) *TRPV1* is a regulator of cell homeostasis, previous studies have revealed that the expression of *TRPV1* is significantly decreased in renal cell carcinoma, colorectal cancer, and melanoma. In addition, *TRPV1* can affect P53 and *TRPV1*-dependent pathways to inhibit the growth of colorectal cancer and melanoma ([@B46]--[@B48]), and can cause apoptosis in human osteosarcoma MG63 cells ([@B49]).

At present, there are few studies on the above three genes *F2, GOT2, TRPV1* and particular their combinations in the prognosis of HCC. In our study, the results of the 20 pairs of HCC and paracancerous tissues for qRT-PCR, as well as 90 pairs HCC biochips for IHC confirmed that all of the *F2, GOT2*, and *TRPV1* genes are significantly and consistently down-expressed in HCC tissues, and this is reconfirmed by three independent microarrays. Moreover, the low expression of *F2, GOT2*, and *TRPV1* were all significantly associated with poor prognosis of HCC. However, due to the number of death events in the *F2-GOT2-TRPV1* high expression group of in the HCC biochips being 0, the survival analysis of the *F2-GOT2-TRPV1* high and the expression group was marginally significant (*p* = 0.051), but this is still consistent with our above-mentioned big data-based multi-gene combination survival analysis results.

As there may be certain relationships between the genes we screened that are significantly associated with the prognosis of liver cancer, they can work together in the form of multi-gene combinations in the development of liver cancer. However, the predictive potency of different gene combinations varies. Some combinations are better predictors than individual genes, and therefore these combinations may be more valuable than individual genes in determining the target site for liver cancer prognosis. Due to limitations in human and material resources, it still remains unclear how these genes and gene combinations specifically affect the HCC survival. Further investigation and experimentations are needed to elucidate the biological mechanisms of the selected genes, particularly for the significant multi-gene combinations, in the development and progression of HCC.

Our findings cover a large gene level, and we have also explored the predictive efficacy of a number of gene combinations for the prognosis of liver cancer. We believe that these highly significant prognostic-related genes and gene combinations derived from the above multiple screenings are promising, reliable molecular markers for the prognosis of liver cancer, and our screening methods can be extended to other tumor types.

In conclusion, based on a large sample size of public data platform, novel and effective data mining and multiple screening methods, large-scale survival analyses, as well as supplemental reliable experimental verification, we identified a series of novel genes and multi-gene combinations that are significantly associated with DFS or OS in liver cancer. Moreover, a huge difference between high and low expression group of these three-gene combination was detected. Some of the three-gene combinations can predict much longer or shorter survival time for liver cancer patients than the single genes. QRT-PCR, immunohistochemistry, and three independent microarray results confirmed our findings that three of the selected novel genes *F2, GOT2*, and *TRPV1*, as well as the corresponding combination *F2-GOT2-TRPV1*, showed significantly lower expression in HCC and are associated with OS in HCC. Some gene combinations may be more predictors of prognosis than single genes and can be used as potential effective therapeutic targets for liver cancer.
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